Want to make the most of ASGCT 2026? Start here.

Booth #1549 | Boston, MA | May 13-15, 2026

Viralgen has everything you need to maximize your AAV gene therapy manufacturing opportunities.

It starts with an unmatched track record — including 30+ serotypes, over 1,500 AAV runs, and a 100% IND/IMPD dossier submission success rate.

We put all that experience into action with Aava™, the high-performance manufacturing platform that delivers better predictability, superior speed, and deeper data. Even better, you can choose Aava Mendi—built for speed and stability—or Aava Iturri—made for scale and efficiency—to get the best match for your strategic goals.

Let’s meet up in Boston. And see just how far your gene therapy can go from there.

Schedule a Meeting

Sponsored Sessions

60 Minute Lunch Symposium

A Platform’s Path to Rare Disease Patients: Accelerating AAV Manufacturing from Development to Commercialization

Wednesday, May 13, 12:15-1:15pm
Location: 107ABC. Lunch to be provided. 

Featured Speakers:
Adrian Stecyk - Myrtelle
Andrew Steinsapir - Apertura
César Trigueros - Viralgen
Craig Martin - Orphan Tx Accelerator
Chrissy Green - Finding Hope for Frizzle

Tools & Technology Presentation

Plasmid Optimization Services: Key Insights from a Case Study Showing how to Successfully Manufacture an AAV Product

Wednesday, May 13, 10:15-10:30am
Location: Exhibit Hall Presentation Theater

Featured Speaker:
Leticia Agúndez - Viralgen

Poster Presentations

PCR-based Quantification and Fragment Analysis of Residual E1A in rAAV Products: Method Validation and Correlation with Total Host Cell DNA

May 12, 5:00pm - 6:30pm
Presented by Maria Garcia

Repeatability and intermediate precision of a genome integrity assay for rAAV by long-read sequencing

May 12, 5:00pm - 6:30pm
Presented by Emilie Lecomte

Multivariate approach to Small-Scale Model Qualification (SSMQ) in Upstream (USP) adeno-associated virus (AAV) production

May 14, 5:00pm - 6:30pm
Presented by Ainara Apezteguia

Say hello to

Aava wordmark white

 

The first choice in AAV gene therapy manufacturing now has a first name. Learn more about the most proven platform in the industry, available only from Viralgen.

Fresh research on AAV manufacturing

Stop by Poster Hall 12 throughout the week for a quintet of research updates from the scientific and technology leads at Viralgen who are helping shape the future of AAV-based gene therapy manufacturing.

Streamlining Advanced Therapy Medicinal Product Manufacturing: A Platform Approach for Accelerating Gene Therapy Commercialization at Viralgen
Presented by Cesar Trigueros
May 15, 5:30-7pm CT
Poster Hall I2
Poster # AMA988

Benefits of High-Throughput Sequencing-Based Methods for In-Depth Characterization of Recombinant AAV Products
Presented by Sonia Stinus
May 14, 5:30-7pm CT
Poster Hall I2
Poster # AMA905

Enhancing the Upstream Performance of Adeno-Associated Virus (AAV) Vector Manufacturing via Multivariate Data Analysis
Presented by Ainara Apezteguia
May 15, 5:30-7pm CT
Poster Hall I2
Poster # AMA1624

Leveraging Historical Data and Percentile based Modeling for Improved AAV Production Scaling
Presented by Itsasne Arangoa
May 15, 5:30-7pm CT
Poster Hall I2
Poster # AMA1546

Integrating Raman Spectroscopy and Genome-Scale Modeling to Enhance AAV Upstream Manufacturing
Presented by Itsasne Arangoa
May 13, 6-7:30pm CT
Poster Hall I2
Poster # AMA1539

Let’s Connect

Bayer fully supports coordinated vulnerability disclosure and encourages security researchers who choose to engage in these actions to do so in a responsible manner.

Coordinated Vulnerability Disclosure Statement

Dig deeper into scaling gene therapies
Proven Progress: Viralgen’s Rare Disease Day Demonstrates the Value of Collaboration
Proven Progress: Viralgen’s Rare Disease Day Demonstrates the Value of Collaboration
If you were tasked with picking a single adjective to describe the global rare disease community, “relentless” would fit naturally at the top of the list. With 95% of the more than 6,000 identified rare diseases worldwide having no current...
READ MORE
March 30, 2026
The Problem of Partials: Redefining the Analytical Frameworks Surrounding Capsid Characterization
The Problem of Partials: Redefining the Analytical Frameworks Surrounding Capsid Characterization
As adeno-associated viral vector (AAV) manufacturing has evolved from research-scale production to commercial operations, the limitations of traditional characterization methods have become impossible to ignore. What was once acceptable...
READ MORE
March 04, 2026
Science in Action: Shared Time, Shared Purpose
Science in Action: Shared Time, Shared Purpose
Science in Action: Shared Time, Shared Purpose At Viralgen, our work is driven by a clear mission: applying science to improve people’s lives. Last December, that mission extended beyond our laboratories and into the community. Across Viralgen and...
READ MORE
December 17, 2025

Please review the following rules: